Cite
HARVARD Citation
Howard, J. et al. (2021). Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet neurology. 20 (7), pp. 526-536. [Online].